Jeff Yass’s Apogee Therapeutics APGE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-27,256
Closed -$3.62M – 13439
2026
Q2
$3.62M Buy
27,256
+11,157
+69% +$1.01M ﹤0.01% 5240
2026
Q1
$1.36M Buy
16,099
+11,465
+247% +$833K ﹤0.01% 7143
2025
Q4
$350K Sell
4,634
-12,055
-72% -$759K ﹤0.01% 9588
2025
Q3
$663K Sell
16,689
-22,008
-57% -$840K ﹤0.01% 8336
2025
Q2
$1.68M Sell
38,697
-31,641
-45% -$1.2M ﹤0.01% 6170
2025
Q1
$2.63M Buy
70,338
+39,050
+125% +$1.51M ﹤0.01% 4935
2024
Q4
$1.42M Sell
31,288
-20,242
-39% -$1.03M ﹤0.01% 6090
2024
Q3
$3.03M Buy
51,530
+36,407
+241% +$1.74M ﹤0.01% 4523
2024
Q2
$595K Sell
15,123
-1,535
-9% -$74.5K ﹤0.01% 7851
2024
Q1
$1.11M Buy
16,658
+7,177
+76% +$313K ﹤0.01% 6647
2023
Q4
$265K Buy
+9,481
New +$190K ﹤0.01% 10087

Other funds holding APGE

Jeff Yass's APGE Position: Q3 2026 in Review

Jeff Yass sold out of Apogee Therapeutics (APGE) in Q3 2026, closing a stake of 27,256 shares — an estimated $3.62M sold.

Jeff Yass first reported a position in APGE in Q4 2023 and held it in 11 quarters. The position peaked at $3.62M in Q2 2026. 2 funds tracked by Wall St. Rank hold APGE as of Q3 2026.

  • Jeff Yass reported no remaining Apogee Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Jeff Yass sold 27,256 Apogee Therapeutics shares in Q3 2026, an estimated $3.62M.
  • Jeff Yass first reported a position in Apogee Therapeutics in Q4 2023 and held it in 11 quarters.
  • Jeff Yass's Apogee Therapeutics position peaked at $3.62M in Q2 2026.
  • 2 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q3 2026.

Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.